FY2025 EPS Estimates for BCRX Increased by Cantor Fitzgerald

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research note issued on Tuesday, May 6th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnology company will earn $0.09 per share for the year, up from their prior estimate of ($0.27). Cantor Fitzgerald has a “Overweight” rating and a $20.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same period in the prior year, the company posted $0.28 EPS. BioCryst Pharmaceuticals’s revenue was up 40.8% compared to the same quarter last year.

A number of other research analysts also recently issued reports on the company. Evercore ISI upped their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Barclays raised their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a report on Wednesday. Needham & Company LLC lifted their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price objective for the company. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $16.56.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $9.92 on Thursday. BioCryst Pharmaceuticals has a 52 week low of $5.06 and a 52 week high of $11.11. The firm has a 50-day moving average price of $7.84 and a two-hundred day moving average price of $7.88. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -16.26 and a beta of 1.08.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. XTX Topco Ltd lifted its stake in shares of BioCryst Pharmaceuticals by 314.8% in the 1st quarter. XTX Topco Ltd now owns 87,389 shares of the biotechnology company’s stock valued at $655,000 after purchasing an additional 66,320 shares during the period. GSA Capital Partners LLP raised its stake in shares of BioCryst Pharmaceuticals by 69.3% in the first quarter. GSA Capital Partners LLP now owns 278,552 shares of the biotechnology company’s stock worth $2,089,000 after purchasing an additional 114,068 shares during the last quarter. Federated Hermes Inc. lifted its stake in BioCryst Pharmaceuticals by 10.1% during the 1st quarter. Federated Hermes Inc. now owns 184,904 shares of the biotechnology company’s stock valued at $1,387,000 after acquiring an additional 16,947 shares during the period. Mackenzie Financial Corp boosted its holdings in BioCryst Pharmaceuticals by 37.3% in the first quarter. Mackenzie Financial Corp now owns 116,258 shares of the biotechnology company’s stock worth $872,000 after purchasing an additional 31,596 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth $125,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.